Loading
Everything OnCo dates to 2022: 665 entries, 158 papers, 134 papers listed on people's pages, 124 landmarks and 98 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
665 dated entries in OnCo fall in 2022: 158 papers, 134 papers listed on people's pages, 124 landmarks, 98 trials reported, 66 approvals, 40 regulatory events, 24 financing rounds, 8 guideline changes, 4 laws and regulations, 4 technologies, 2 companies founded, 2 journals founded and 1 expected date.
Of those, 25 to the day, 24 to the month and 616 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
KRAS G12C NSCLC (accelerated)
Locally advanced or metastatic non-small-cell lung cancer with an EGFR exon 20 insertion after platinum-based chemotherapy: not recommended.
Second-line LBCL refractory or relapsed within 12 months
Recurrent/metastatic cervical cancer after platinum
Tepmetko 2022; Tabrecta 2022
Prevention of HPV 6/11/16/18-related cancers and genital warts, ages 9-26. Market authorisation from the DCGI in 2022; introduced 2023
Relapsed/refractory myeloma ≥4 lines
Histiocytic neoplasms
ALK-positive inflammatory myofibroblastic tumour
BRAF V600E solid tumours, tumour-agnostic (age ≥6)
mHSPC with docetaxel (ARASENS)
Radioiodine-refractory differentiated thyroid cancer
Locally advanced unresectable non-small-cell lung cancer with PD-L1 on 1 percent or more of cells that has not progressed after concurrent platinum-based chemoradiation.
Locally advanced or metastatic biliary tract cancer (gallbladder cancer included) with gemcitabine and cisplatin (TOPAZ-1).
To decrease the incidence of febrile neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy
mUC after platinum + PD-1; 1L with pembrolizumab 2024
First-line EGFR exon 19 deletion or L858R NSCLC (FURLONG)
Previously treated FGFR2-fusion/rearranged intrahepatic cholangiocarcinoma (accelerated)
PATHWAY 4B5 as companion diagnostic for trastuzumab deruxtecan in HER2-low breast cancer
Fixed-duration ibrutinib + venetoclax, first-line CLL (GLOW, CAPTIVATE)
Newly diagnosed IDH1-mutated AML with azacitidine (AGILE)
Relapsed or refractory follicular lymphoma after two or more lines, conditional
Second-line LBCL (TRANSFORM)
PSMA PET in prostate cancer
PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy
R/R DLBCL ≥2 lines (conditional)
mCRPC post-ARPI and taxane; pre-chemo 2025
PSMA+ mCRPC after ARPI and taxane
FRα-high platinum-resistant ovarian cancer (full approval 2024)
R/R follicular lymphoma after ≥2 lines (accelerated)
BCG-unresponsive high-risk NMIBC with CIS ± papillary tumours
Single-dose schedule recommended for girls 9-20
Adjuvant treatment, alone or with endocrine therapy, of germline BRCA1/2-mutated HER2-negative high-risk early breast cancer after neoadjuvant or adjuvant chemotherapy (OlympiA).
Adjuvant gBRCA high-risk HER2- early breast cancer
Relapsed/refractory IDH1-mutated AML
Intermediate/high-risk myelofibrosis with platelets <50×10⁹/L
Intraoperative identification of lung lesions
Untreated metastatic squamous non-small-cell lung cancer, with carboplatin and paclitaxel. TA770, published 9 February 2022, for a tumour proportion score of 0 to 49 percent, or 50...
Locally advanced or early-stage TNBC at high risk of recurrence: neoadjuvant with chemotherapy, then adjuvant monotherapy (KEYNOTE-522).
Untreated triple-negative locally recurrent unresectable or metastatic breast cancer with paclitaxel or nab-paclitaxel; NICE TA801 (29 June 2022) recommends it only for tumours wit...
Neoadjuvant with chemotherapy then adjuvant alone for triple-negative early breast cancer at high risk of recurrence or locally advanced disease; NICE TA851 (14 December 2022) reco...
RET fusion-positive advanced non-small-cell lung cancer in patients who have not had a RET inhibitor: not recommended.
Previously treated MSI-high or dMMR advanced solid tumours; unresectable or metastatic melanoma after prior therapy
Melanoma, PD-L1 <1% restriction
Unresectable or metastatic melanoma, age ≥12
Relapsed or refractory follicular lymphoma after two or more lines
Companion diagnostic for adagrasib in KRAS G12C-mutant NSCLC (plasma)
High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy
Unresectable triple-negative locally advanced or metastatic breast cancer after two or more systemic therapies, at least one for advanced disease; NICE TA819 (17 August 2022) recom...
RET-fusion solid tumours (tumour-agnostic)
First-line ES-SCLC with chemotherapy
First-line oesophageal squamous cell carcinoma with chemotherapy (ORIENT-15)
Reduce risk of ototoxicity from cisplatin in patients ≥1 month with localised, non-metastatic solid tumours
KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer that has progressed on, or after intolerance of, platinum-based chemotherapy or PD-1/PD-L1 imm...
EU brand Lumykras. Conditional marketing authorisation
Unresectable stage III NSCLC without progression after chemoradiotherapy (GEMSTONE-301)
Relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after at least one prior therapy
HLA-A*02:01+ metastatic uveal melanoma
R/R myeloma ≥3 lines (conditional, Aug 2022). Conditional marketing authorisation
Relapsed/refractory myeloma after ≥4 lines
Advanced non-small-cell lung cancer with MET exon 14 skipping alterations. TA789, published 18 May 2022, subject to the commercial arrangement (VISION).
Advanced NSCLC with MET exon 14 skipping alterations after immunotherapy or platinum chemotherapy
Relapsed/refractory follicular lymphoma
HER2-low metastatic breast cancer; HER2-mutant NSCLC
Metastatic NSCLC without EGFR/ALK, with durvalumab and platinum chemotherapy; unresectable HCC with durvalumab
CE-IVD comprehensive genomic profiling
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
RMAT designation, CLDN18.2+ gastric cancer
Breakthrough Therapy designation, c-MET overexpressing NSCLC
HLA-A*02:01+ unresectable or metastatic uveal melanoma: first TCR therapeutic approved
Relapsed/refractory myeloma after ≥4 lines (CARTITUDE-1)
First generics launch (volume-limited)
Complete response letter for ORIENT-11 (first-line non-squamous NSCLC); ODAC voted 14 to 1 that additional data were needed for US applicability
Neoadjuvant NSCLC with chemotherapy (CheckMate 816)
Adjuvant gBRCA high-risk HER2-negative early breast cancer (OlympiA)
Unresectable or metastatic melanoma, age ≥12 (RELATIVITY-047): first LAG-3 therapy
PSMA+ mCRPC after ARPI and taxane (VISION)
First nab-paclitaxel generics
EMA approval
Second-line LBCL refractory or relapsed within 12 months (ZUMA-7)
Label updated with INTRIGUE data
Merck licenses ex-Greater-China rights (deal expanded December 2022)
Second-line HER2+ metastatic breast cancer (DESTINY-Breast03)
Combination with azacitidine (AGILE)
Later-line treatment indication withdrawn after ARIEL4 OS imbalance
First PD-1×CTLA-4 bispecific approved anywhere
Tablet formulation co-administrable with acid-reducing agents
HER2-low metastatic breast cancer (DESTINY-Breast04); first HER2-low indication
HER2-mutant NSCLC (accelerated)
Conditional approval: first BCMA bispecific worldwide
EMA approval, PD-L1 <1% melanoma
Biliary tract cancer with chemotherapy (TOPAZ-1)
RET-fusion solid tumours (tumour-agnostic, accelerated); full approval in NSCLC
HCC with tremelimumab (HIMALAYA)
Accelerated approval, relapsed/refractory myeloma after ≥4 lines (MajesTEC-1)
Second-line maintenance restricted to gBRCA after OS data
Breakthrough Therapy designation, ES-SCLC after platinum
Paediatric high-risk Hodgkin lymphoma
Accelerated approval, FRα-high platinum-resistant ovarian cancer (SORAYA)
Withdrawn after DREAMM-3 failed to confirm benefit
Conditional marketing authorisation
EMA approval
One-dose schedule endorsed (SAGE)
Breakthrough Therapy designation
Study 2102-HEM-101 pivotal cohort
Clovis Oncology bankruptcy; asset sold to pharma&
Accelerated approval, KRAS G12C NSCLC after ≥1 therapy
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
United States, statute.
United States, statute.
United Kingdom, scheme.
United Kingdom, guidance.
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
2 rows added. Anchored to Annals of Oncology publication, 2022.
2 rows added. Anchored to FDA approvals of adjuvant pembrolizumab for stage IIB-IIC (December 2021, KEYNOTE-716) and nivolumab plus relatlimab (March 2022, RELATIVITY-047).
1 row recategorised. Anchored to FDA approval of trastuzumab deruxtecan in the second line, May 2022 (DESTINY-Breast03).
1 row recategorised. Anchored to FDA approvals of axicabtagene ciloleucel (April 2022, ZUMA-7) and lisocabtagene maraleucel (June 2022, TRANSFORM) in the second line.
2 rows added. Anchored to FDA approvals of 177Lu-PSMA-617 (March 2022, VISION) and darolutamide with docetaxel (August 2022, ARASENS).
2 rows added. Anchored to FDA approvals of adjuvant olaparib for germline BRCA carriers (March 2022, OlympiA) and trastuzumab deruxtecan for HER2-low disease (August 2022, DESTINY-...
2 rows added. Anchored to Annals of Oncology publication, 2022.
1 row removed, 1 row added. Anchored to Sponsor withdrawals of later-line PARP inhibitor treatment indications (June to September 2022) after overall-survival signals; FDA accelera...
The year reported on trial records, with the headline result the record gives.
Bortezomib did not significantly improve four-year event-free survival for the whole group (83.8 against 80.1 percent) but did for T-lymphoblastic lymphoma; cranial radiotherapy wa...
PFS 19.3 vs 9.9 months, HR 0.46.
OS 24.0 vs 7.9 months; HR 0.44.
Three-year event-free survival 92.1 percent with brentuximab vedotin plus AVEPC against 82.5 percent with ABVE-PC (hazard ratio 0.41, p < 0.001), with no increase in toxicity; appr...
18-month overall survival 66.7 percent with neoadjuvant modified FOLFIRINOX alone against 47.3 percent with chemotherapy plus hypofractionated radiotherapy; the radiotherapy arm cl...
PFS HR 0.65; AF 5.2% vs 13.3%.
Progression to anal cancer 173 per 100,000 person-years with treatment against 402 with active monitoring, a 57 percent reduction (95% CI 6 to 80, p 0.03); the trial stopped early...
PFS 4.3 vs 4.5 months, HR 1.22; primary endpoint not met.
OS HR 0.68.
OS 15.4 vs 10.9 months, HR 0.63.
PFS 20.2 vs 9.2 months (HR 0.52).
2-year DFS 56.6% (genomically directed) vs 62.4% (physician's choice); no difference in DFS, DDFS or OS. Post-surgical ctDNA predicted outcome.
PFS HR 0.60 overall; HR 0.50 in AKT-pathway-altered.
OS 15.3 vs 12.8 months, HR 0.72.
OS 28.9 vs 32.1 months, HR 1.1 (95% CI 0.9-1.3); no PFS or OS benefit.
EFS HR 0.63; OS HR 0.72.
Nivolumab plus low-dose ipilimumab did not improve recurrence-free survival over nivolumab alone after resection of stage III to IV melanoma.
Objective response 30 percent (8 of 27) and disease control 63 percent in ctDNA-selected patients; 31 percent of those screened were excluded by a resistance mutation.
PFS HR 0.66; OS HR 1.01.
PFS HR 0.73; OS HR 1.02 (no benefit).
PFS HR 0.29; ORR 41% vs 8%.
OS HR 0.64.
High response rate with durable responses in HER2-mutant non-small-cell lung cancer; accelerated approval in August 2022.
Early autologous transplant added to RVd and lenalidomide maintenance prolonged progression-free survival; overall survival did not differ at the primary analysis.
Chemotherapy use 15% vs 28% with non-inferior RFS.
Two-year progression-free survival 96.9% (observation), 94.9% (50 Gy), 96.0% (60 Gy) and 90.7% (high-risk chemoradiation).
ORR 63%, CR 39%.
3-year event-free 95.6% vs 95.9% (non-inferior).
ORR 42%; PFS 9.0 months; OS 21.7 months.
PFS 20.8 vs 11.1 months, HR 0.44.
Median progression-free survival 9.0 against 5.8 months by blinded independent review, including after sequential chemoradiotherapy.
PFS 7.8 vs 4.9 months, HR 0.50.
Clinically insignificant cancer 0.6% vs 1.2% (RR 0.46); clinically significant cancer 0.9% vs 1.1%.
OS HR 0.78; 5-year OS 19.6% vs 9.4%.
Overall survival not improved: stratified hazard ratio 1.12 (95 percent confidence interval 0.91 to 1.37, p=0.28) for atezolizumab with enzalutamide against enzalutamide alone.
Segmentectomy was superior to lobectomy for overall survival; in the pure-solid subgroup five-year overall survival was 92.4 against 86.1 percent (hazard ratio 0.64).
OS 17.0 vs 11.0 months (HR 0.58); PFS HR 0.58.
Single-dose efficacy 97.5% against persistent HPV16/18.
Disease-free survival significantly improved in the overall population; the co-primary endpoint in the PD-L1 50 percent or greater population was not met.
Pembrolizumab added to chemoradiotherapy did not significantly improve event-free survival.
OS HR 0.84, not significant.
Median PFS 12.2 vs 6.2 months (HR 0.41); overall survival also favoured the combination at later follow-up.
Median overall survival 14.5 months with ramucirumab plus pembrolizumab versus 11.6 months with standard of care (hazard ratio 0.69); confirmation sought in the phase 3 Pragmatica-...
BRCA cohort rPFS HR 0.53; HRR-negative futility.
ORR 63%, ≥CR 39%.
ORR ~73%.
Phase 2 ORR 38.1%, DOR 12.4 months; phase 3 ongoing.
Actionable alteration in 31.5% of the first 1,000 tumours; 28.4% assigned and 13.1% enrolled on a treatment arm.
Pathological complete response in 40 of 79 patients (51 per cent, 95 per cent confidence interval 39 to 62) and pathological major response in a further 13 per cent, with grade 3 o...
pCR 48.6% vs 44.4% (OR 1.18, p 0.48), not significant; EFS (primary) awaited.
pCR 68%, major pathologic response 95%; 3-year DFS 100%.
10-year colorectal cancer risk 0.98% vs 1.20% (RR 0.82) by invitation; mortality RR 0.90, not significant.
3-year disease-free survival 76% in both arms; 3-year survival without total mesorectal excision 41% (induction) vs 53% (consolidation).
OS 37.9 vs 34.3 months (HR 0.82) in left-sided RAS wild-type disease.
5-year OS 20.5% vs 6.5% (HR 0.73, p 0.025); primary analysis median OS 16.0 vs 14.3 months (HR 0.78, p 0.096).
rPFS HR 0.66 (ITT); OS HR 0.81 (NS).
Five-year freedom from progression after prostatectomy 70.9 percent with prostate bed radiotherapy alone, 81.3 percent with added short-term androgen deprivation and 87.4 percent w...
OS 31.9 vs 15.1 months; HR 0.776.
CR 71%.
OS 8.6 vs 6.3 months, HR 0.70.
OS 17.2 vs 10.6 months (HR 0.66); PD-L1 ≥1% OS 16.8 vs 9.6 months.
PFS HR 0.75; median OS 51.0 vs 34.1 months.
PFS HR 0.42 vs BR; 5-year PFS 72.2% in del(17p).
Objective responses in about a third of patients with folate receptor alpha-high platinum-resistant ovarian cancer; accelerated approval in November 2022.
Three-year disease-free survival 64.5 against 62.3 percent, non-inferior; more acute toxicity before surgery.
Durvalumab with chemotherapy improved progression-free survival (5.5 against 4.8 months, hazard ratio 0.74, p=0.0009) but not significantly overall survival; adding a limited cours...
2-year EFS 72% vs 49%; HR 0.58.
OS HR 0.76; 2-year OS 23.6% vs 11.5%.
EFS HR 0.36; CR 74% vs 43%.
ORR 9.4% vs 4.8%; PFS 2.83 vs 2.79 months, HR 0.90; OS 7.8 vs 7.5 months, HR 1.11; gallbladder subgroup PFS 2.9 vs 1.6 months, HR 0.55 (0.26 to 1.19).
OS 14.4 vs 11.2 months, HR 0.79.
Intracranial responses in most patients with active HER2-positive breast cancer brain metastases.
Physical function at five weeks 4.65 points better after keyhole surgery; serious adverse events after discharge 30.7 against 37.8 percent; no difference in progression-free or ove...
The publication year on key paper records.
Andrikopoulou A, Chatzinikolaou S, Panourgias E, et al. The Breast.
Lyon AR, López-Fernández T, Couch LS, et al. European heart journal.
Teachey DT, Devidas M, Wood BL, et al. Journal of Clinical Oncology.
Pollard JA, Alonzo TA, Gerbing R, et al. Journal of Clinical Oncology.
Al-Hallaq HA, Cerviño L, Gutierrez AN, et al. Medical physics.
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. NEJM Evidence.
Fizazi K, Foulon S, Carles J, et al. The Lancet.
Bartels U, Onar-Thomas A, Patel SK, et al. Neuro-Oncology.
Parsons DW, Janeway KA, Patton DR, et al. Journal of Clinical Oncology.
Jänne PA, Riely GJ, Gadgeel SM, et al. New England Journal of Medicine.
Wang J, Zhou C, Yao W, et al. The Lancet Oncology.
Lu S, Dong X, Jian H, et al. Journal of Clinical Oncology.
Martini R, Delpe P, Chu TR, et al. Cancer Discovery.
Montesinos P, Recher C, Vives S, et al. New England Journal of Medicine.
Castellino SM, Pei Q, Parsons SK, et al. New England Journal of Medicine.
Katz MHG, Shi Q, Meyers J, et al. JAMA Oncology.
Palefsky JM, Lee JY, Jay N, et al. New England Journal of Medicine.
Kindler HL, Novello S, Bearz A, et al. The Lancet Oncology.
Smith MR, Hussain M, Saad F, et al. New England Journal of Medicine.
Aminian A, Wilson R, Al-Kurd A, et al. JAMA.
Ricciuti B, Wang X, Alessi JV, et al. JAMA Oncology.
Friedman CF, Hainsworth JD, Kurzrock R, et al. Cancer Discovery.
Peters S, Dziadziuszko R, Morabito A, et al. Nature Medicine.
Reig M, Forner A, Rimola J, et al. Journal of Hepatology.
Andre F, Ismaila N, Allison KH, et al. Journal of Clinical Oncology.
Henry NL, Somerfield MR, Dayao Z, et al. Journal of Clinical Oncology.
Johnson SB, Parsons M, Dorff T, et al. JNCI: Journal of the National Cancer Institute.
Farwell MD, Gamache RF, Babazada H, et al. Journal of Nuclear Medicine.
Cercek A, Lumish M, Sinopoli J, et al. New England Journal of Medicine.
Upadhaya S, Neftelinov ST, Hodge J, et al. Nature Reviews Drug Discovery.
Hoang R, Temple C, Correia MS, Clemons J, Hendrickson RG. Clinical Toxicology.
Doki Y, Ajani JA, Kato K, et al. New England Journal of Medicine.
Forde PM, Spicer J, Lu S, et al. New England Journal of Medicine.
Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, et al. Frontiers in immunology.
Henriksen TV, Tarazona N, Frydendahl A, et al. Clinical Cancer Research.
Herbst RS, Majem M, Barlesi F, et al. Journal of Clinical Oncology.
Giraldo NA, Drill E, Satravada BA, et al. Clinical Cancer Research.
Almogy G, Pratt M, Oberstrass F, et al. bioRxiv (preprint).
Subbiah V, Kreitman RJ, Wainberg ZA, et al. Annals of Oncology.
Cortes J, Kim SB, Chung WP, et al. New England Journal of Medicine.
Modi S, Jacot W, Yamashita T, et al. New England Journal of Medicine.
Li BT, Smit EF, Goto Y, et al. New England Journal of Medicine.
Berchuck JE, Baca SC, McClure HM, et al. Clinical Cancer Research.
Stopsack KH, Nandakumar S, Arora K, et al. Clinical Cancer Research.
Ricciuti B, Arbour KC, Lin JJ, et al. Journal of Thoracic Oncology.
Tie J, Cohen JD, Lahouel K, et al. New England Journal of Medicine.
Crosby D, Bhatia S, Brindle KM, et al. Science.
Ferris RL, Flamand Y, Weinstein GS, et al. Journal of Clinical Oncology.
Basch E, Schrag D, Henson S, et al. JAMA.
Cheng Y, Han L, Wu L, et al. JAMA.
Goodwin PJ, Chen BE, Gelmon KA, et al. JAMA.
Pellacani G, Farnetani F, Ciardo S, et al. JAMA dermatology.
Post CCB, Westermann AM, Boere IA, et al. Gynecologic Oncology.
Barnabas RV, Brown ER, Onono MA, et al. NEJM Evidence.
Döhner H, Wei AH, Appelbaum FR, et al. Blood.
Bidard FC, Kaklamani VG, Neven P, et al. Journal of Clinical Oncology.
Tewari KS, Monk BJ, Vergote I, et al. New England Journal of Medicine.
Crosbie EJ, Kitson SJ, McAlpine JN, et al. The Lancet.
Leboulleux S, Bournaud C, Chougnet CN, et al. New England Journal of Medicine.
Babjuk M, Burger M, Capoun O, et al. European Urology.
Fernandez AI, Liu M, Bellizzi A, et al. JAMA Oncology.
Brown LC, Graham J, Fisher D, et al. Clinical trials (London, England).
Stockwell BR. Cell.
Zhang L, Wang Z, Fang J, et al. Lung cancer.
Conroy T, Castan F, Lopez A, et al. JAMA Oncology.
Spigel DR, Faivre-Finn C, Gray JE, et al. Journal of Clinical Oncology.
Howell SJ, Casbard A, Carucci M, et al. The Lancet Oncology.
Kornauth C, Pemovska T, Vladimer GI, et al. Cancer Discovery.
Shi Y, Chen G, Wang X, et al. The Lancet. Respiratory medicine.
Roa JC, García P, Kapoor VK, et al. Nature Reviews Disease Primers.
Casali PG, Blay JY, Abecassis N, et al. Annals of Oncology.
Majzner RG, Ramakrishna S, Yeom KW, et al. Nature.
Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. New England Journal of Medicine.
Gershenson DM, Miller A, Brady WE, et al. The Lancet.
Powell MA, Filiaci VL, Hensley ML, et al. Journal of Clinical Oncology.
Hanahan D. Cancer Discovery.
Saxena S, Zou L. Molecular cell.
Hietanen E, Koivu MKA, Susi P. Viruses.
Abou-Alfa GK, Lau G, Kudo M, et al. NEJM Evidence.
Cai L, Tao T, Li H, et al. Journal of global health.
Sinicrope FA. New England Journal of Medicine.
Mao JJ, Ismaila N, Bao T, et al. Journal of Clinical Oncology.
Tree AC, Ostler P, van der Voet H, et al. The Lancet Oncology.
Arber DA, Orazi A, Hasserjian RP, et al. Blood.
Bauer S, Jones RL, Blay JY, et al. Journal of Clinical Oncology.
Bernard E, Tuechler H, Greenberg PL, et al. NEJM Evidence.
Cortes J, Rugo HS, Cescon DW, et al. New England Journal of Medicine.
Schmid P, Cortes J, Dent R, et al. New England Journal of Medicine.
Luke JJ, Rutkowski P, Queirolo P, et al. The Lancet.
Makker V, Colombo N, Casado Herráez A, et al. New England Journal of Medicine.
Pautier P, Italiano A, Piperno-Neumann S, et al. The Lancet Oncology.
Geyer CE, Sikov WM, Huober J, et al. Annals of Oncology.
Ferreri AJM, Cwynarski K, Pulczynski E, et al. Leukemia.
Jia AY, Kashani R, Zaorsky NG, et al. Practical radiation oncology.
Moreau P, Garfall AL, van de Donk NWCJ, et al. New England Journal of Medicine.
Foley KG, Lahaye MJ, Thoeni RF, et al. European Radiology.
Haanen J, Obeid M, Spain L, et al. Annals of Oncology.
Philip PA, Azar I, Xiu J, et al. Clinical Cancer Research.
Chari A, Minnema MC, Berdeja JG, et al. New England Journal of Medicine.
Marron TU, Fiel MI, Hamon P, et al. The lancet. Gastroenterology & hepatology.
Gross ND, Miller DM, Khushalani NI, et al. New England Journal of Medicine.
Neal RD, Johnson P, Clarke CA, et al. Cancers.
Dizman N, Meza L, Bergerot P, et al. Nature Medicine.
Bretthauer M, Løberg M, Wieszczy P, et al. New England Journal of Medicine.
Garcia-Aguilar J, Patil S, Gollub MJ, et al. Journal of Clinical Oncology.
Geyer CE, Garber JE, Gelber RD, et al. Annals of Oncology.
Hortobagyi GN, Stemmer SM, Burris HA, et al. New England Journal of Medicine.
Alausa A, Lawal KA, Babatunde OA, et al. Pharmacological research.
Maio M, Ascierto PA, Manzyuk L, et al. Annals of Oncology.
O'Malley DM, Bariani GM, Cassier PA, et al. Journal of Clinical Oncology.
Yu EY, Kolinsky MP, Berry WR, et al. European Urology.
Diaz LA, Shiu KK, Kim TW, et al. The Lancet Oncology.
Long GV, Luke JJ, Khattak MA, et al. The Lancet Oncology.
Gupta R, Meric-Bernstam F, Rothe M, et al. JCO Precision Oncology.
Reckamp KL, Redman MW, Dragnev KH, et al. Journal of Clinical Oncology.
Eckstein OS, Allen CE, Williams PM, et al. Journal of Clinical Oncology.
Lim M, Weller M, Idbaih A, et al. Neuro-Oncology.
Tilly H, Morschhauser F, Sehn LH, et al. New England Journal of Medicine.
Kindler HL, Hammel P, Reni M, et al. Journal of Clinical Oncology.
Powell CA, Modi S, Iwata H, et al. ESMO Open.
Ligorio F, Di Cosimo S, Verderio P, et al. JNCI: Journal of the National Cancer Institute.
Versteijne E, van Dam JL, Suker M, et al. Journal of Clinical Oncology.
Hugosson J, Månsson M, Wallström J, et al. New England Journal of Medicine.
Esteva A, Feng J, van der Wal D, et al. NPJ digital medicine.
Békés M, Langley DR, Crews CM. Nature Reviews Drug Discovery.
Parker CC, James ND, Brawley CD, et al. PLOS Medicine.
Kehl KL, Zahrieh D, Yang P, et al. JAMA Oncology.
Tawbi HA, Schadendorf D, Lipson EJ, et al. New England Journal of Medicine.
Yau C, Osdoit M, van der Noordaa M, et al. The Lancet Oncology.
Rohaas MW, Borch TH, van den Berg JH, et al. New England Journal of Medicine.
van Herpen C, Vander Poorten V, Skalova A, et al. ESMO Open.
Schmitt CA, Wang B, Demaria M. Nature Reviews Clinical Oncology.
Siegel RL, Miller KD, Fuchs HE, Jemal A. CA: A Cancer Journal for Clinicians.
Attard G, Murphy L, Clarke NW, et al. The Lancet.
Zhou C, Wang Z, Sun Y, et al. The Lancet Oncology.
Ishiguro T, Ishiguro RH, Ishiguro M, Toki A, Terunuma H. Cureus.
Marx A, Chan JKC, Chalabreysse L, et al. Journal of Thoracic Oncology.
Pavlova NN, Zhu J, Thompson CB. Cell metabolism.
Dbouk M, Katona BW, Brand RE, et al. Journal of Clinical Oncology.
Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, et al. Nature Reviews Clinical Oncology.
Cho BC, Abreu DR, Hussein M, et al. The Lancet Oncology.
Shen L, Kato K, Kim SB, et al. Journal of Clinical Oncology.
Todo T, Ito H, Ino Y, et al. Nature Medicine.
Oh DY, Ruth He A, Qin S, et al. NEJM Evidence.
Wang ZX, Cui C, Yao J, et al. Cancer Cell.
Rosen DB, Kvarnhammar AM, Laufer B, et al. Journal for ImmunoTherapy of Cancer.
Kamdar M, Solomon SR, Arnason J, et al. The Lancet.
Krop IE, Im SA, Barrios C, et al. Journal of Clinical Oncology.
Vogelbaum MA, Brown PD, Messersmith H, et al. Journal of Clinical Oncology.
Bartsch R, Berghoff AS, Furtner J, et al. Nature Medicine.
Cheng AL, Qin S, Ikeda M, et al. Journal of hepatology.
Korde LA, Somerfield MR, Hershman DL, et al. Journal of Clinical Oncology.
Chalasani NP, Porter K, Bhattacharya A, et al. Clinical gastroenterology and hepatology.
Alaggio R, Amador C, Anagnostopoulos I, et al. Leukemia.
Khoury JD, Solary E, Abla O, et al. Leukemia.
Moch H, Amin MB, Berney DM, et al. European Urology.
Tam CS, Brown JR, Kahl BS, et al. The Lancet Oncology.
Locke FL, Miklos DB, Jacobson CA, et al. New England Journal of Medicine.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Colorectal cancer. DYNAMIC cut adjuvant chemotherapy use in resected stage II colon cancer from 28% to 15% with non-inferior two-year recurrence-free survival, the first randomised...
High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)
Acute myeloid leukaemia in children
KRAS G12C-mutant non-small-cell lung cancer
Triple-negative breast cancer (TNBC). Martini's RNA sequencing of African American, West and East African tumours finds 613 ancestry-associated genes and distinct tumour-associated...
Acute myeloid leukaemia in older or unfit patients
IDH1- and IDH2-mutated acute myeloid leukaemia
Early-stage classical Hodgkin lymphoma (stage I to II)
Borderline resectable pancreatic ductal adenocarcinoma
Relapsed or refractory chronic lymphocytic leukaemia
Anal high-grade squamous intraepithelial lesions (precursor)
Anal cancer (squamous cell carcinoma)
Metastatic hormone-sensitive prostate cancer
Extensive-stage small-cell lung cancer
Platinum-sensitive ovarian cancer
Intermediate hepatocellular carcinoma (BCLC B)
Pancreatic ductal adenocarcinoma. 1,461 high-risk people enrolled; across CAPS1 to 5 (1,731 people) 57.9 percent of the 19 surveillance-detected cancers were stage I, with five-yea...
Oesophageal cancer
Oesophageal squamous cell carcinoma
Non-small-cell lung cancer
Resectable stage I to III non-small-cell lung cancer
Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)
Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms. FDA approval October 2022 for adults with ECD, RDD and LCH.
Erdheim-Chester disease
Rosai-Dorfman-Destombes disease
Inflammatory myofibroblastic tumour (IMT). FDA, 14 July 2022, adults and children aged 1 year and older.
KRAS wild-type pancreatic ductal adenocarcinoma
HER2-low and HER2-ultralow metastatic breast cancer
Metastatic triple-negative breast cancer
HER2-mutant non-small-cell lung cancer
Prostate cancer. Cell-free DNA methylation separates neuroendocrine from castration-resistant adenocarcinoma with near-perfect discrimination in two small cohorts; a 2,069-man sing...
Rectal cancer
Colorectal cancer. Organ preservation without surgery in the first Memorial Sloan Kettering cohort (Cercek, NEJM); panitumumab beat bevacizumab in left-sided RAS wild-type disease.
Biliary tract cancer (all types)
HPV-positive oropharyngeal cancer
Hodgkin lymphoma
Advanced-stage classical Hodgkin lymphoma (stage III to IV)
FLT3-mutated acute myeloid leukaemia
Acute myeloid leukaemia. Genetics-first classification; ivosidenib-azacitidine OS HR 0.44; second IDH1 inhibitor approved.
Salivary gland cancers
Papillary thyroid cancer. Both trials found equivalent outcomes without ablation.
Thyroid cancer
Sarcomas (soft tissue, bone, GIST)
Ewing sarcoma
Follicular lymphoma. Off-the-shelf CD20×CD3 with ~60% CR in third line.
Diffuse midline glioma, H3 K27-altered (including DIPG). Majzner and colleagues (Nature) report clinical and radiographic improvement with intravenous then intracerebroventricular...
Intrahepatic cholangiocarcinoma
Glioma & glioblastoma
Low-grade serous ovarian cancer
Uterine carcinosarcoma
HR-positive / HER2-negative breast cancer
Triple-negative breast cancer (TNBC). DESTINY-Breast04 includes TNBC patients with HER2-low tumours.
Advanced hepatocellular carcinoma (BCLC C)
Hepatocellular carcinoma
Chronic lymphocytic leukaemia. Venetoclax combinations beat chemoimmunotherapy in fit patients; ibrutinib-venetoclax approved in Europe.
Chronic myeloid leukaemia, accelerated and blast phase
Primary CNS lymphoma
Gastrointestinal stromal tumour (GIST)
Imatinib-resistant GIST
Lower-risk myelodysplastic syndromes
Myelodysplastic syndromes / neoplasms (MDS). Molecular risk model with 31 genes; classification renamed myelodysplastic neoplasms with genetically defined entities.
Gallbladder cancer. ESGAR, EAES, EFISDS and ESGE set size and risk-factor rules for cholecystectomy and ultrasound follow-up.
Soft tissue sarcoma of the extremity (localised and advanced)
Uterine sarcoma. Pautier and colleagues, Lancet Oncol.
Leiomyosarcoma
Platinum-resistant ovarian cancer
High-grade serous ovarian cancer
Ovarian cancer. Accelerated approval; full approval after MIRASOL OS benefit in 2024.
Ovarian cancer
Clear cell ovarian cancer
HER2-amplified colorectal cancer
Gallbladder cancer. 244 samples: TP53 63%, CDKN2A 21%, ERBB2 15%, KRAS 11%, actionable alterations in 35% of patients (Giraldo et al., Clinical Cancer Research).
Bladder & urothelial cancer
Non-muscle-invasive bladder cancer
Ampullary cancer (ampulla of Vater). Subtype-directed treatment recommendations formalised.
Cutaneous squamous cell carcinoma
Advanced cutaneous squamous cell carcinoma
Vestibular schwannoma (acoustic neuroma)
Mismatch-repair deficient (MSI-high) colorectal cancer
Melanoma
Colorectal cancer. 84,585 people in Poland, Norway and Sweden; a single invitation cut the 10-year risk of colorectal cancer from 1.20 to 0.98 percent, with 455 invitations needed...
Rectal cancer
Unresectable stage III non-small-cell lung cancer
Primary myelofibrosis
Myeloproliferative neoplasms (PV, ET, myelofibrosis)
HPV-associated vulvar squamous cell carcinoma
Prostate cancer
Diffuse large B-cell lymphoma
Pancreatic ductal adenocarcinoma. Adjuvant modified FOLFIRINOX against gemcitabine: median overall survival 53.5 versus 35.5 months, five-year survival 43.2 versus 31.4 percent, ha...
Metastatic castration-resistant prostate cancer
Endometrial cancer with no specific molecular profile
POLE-ultramutated endometrial cancer
Adenoid cystic carcinoma
Ewing sarcoma
Advanced melanoma (unresectable stage III and stage IV)
Chronic lymphocytic leukaemia, first treatment
Localised prostate cancer, high and very high risk
Stage III melanoma (after surgery)
Post-transplant lymphoproliferative disorder (PTLD). First allogeneic T-cell immunotherapy approved; December 2022, for relapsed or refractory EBV-positive PTLD.
Angiosarcoma
Uveal melanoma. FDA January 2022; EMA April 2022.
Relapsed or refractory multiple myeloma
Multiple myeloma
Multiple myeloma
Lung cancer (all types). After an evidence review and a health economic model, the committee recommended in June 2022 that all four UK nations move towards targeted lung cancer scr...
Gallbladder cancer. First immunotherapy survival benefit in biliary tract cancer; FDA approval September 2022.
Extrahepatic cholangiocarcinoma (perihilar and distal)
Biliary tract cancer (cholangiocarcinoma)
Biliary tract cancer (cholangiocarcinoma)
Paediatric high-grade glioma (excluding diffuse midline glioma)
HER2-positive breast cancer with brain metastases
Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms. Monocyte threshold lowered to 0.5 x 10^9/L with molecular support; dysplastic vs proliferative subtypes formalised.
Indolent and smouldering systemic mastocytosis
Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma
Parathyroid carcinoma. Fifth edition endocrine tumours.
Localised penile cancer (organ-confined, node-negative)
Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)
Papillary renal cell carcinoma
Cervical cancer
Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma. Lineage-based classification.
Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)
Follicular thyroid cancer
Diffuse large B-cell lymphoma
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Paris
San Francisco, CA
The funding rounds on company records, each with the source that states the figure.
IPO closed 17 November 2022 with a concurrent 5 million US dollar private placement to Chione; gross IPO proceeds not stated in the fetched filing
$45m. Total sold of an 85 million US dollar offering per amended Form D filed June 2022
$142m. 9,487,500 shares at $15.00 including full option exercise; Nasdaq ACLX
$76m. Amount sold of a $102 million offering, first sale 14 June 2022 (filed March 2024)
$47m
$21m. Led by Bonnier Ventures, June 2022.
$61m. Led by Avalon Ventures
$17m. Series A2, led by Flerie Invest
$34m. Amount sold at filing of a $67 million offering, first sale 28 January 2022
$50m. Equity offering, first sale 14 April 2022; issuer then based in Cambridge, MA
July 2022, led by Sofinnova Partners and Mérieux Equity Partners; amount not stated in the fetched release copy
GBP 50 million; GBP 62 million equity raised to date per company
$51m. $33.4 million Series A expansion bringing the round to $51 million; led by Gurnet Point Capital with TechU Ventures and BrightEdge, September 2022.
$90m. Led by Goldman Sachs Asset Management; brought total financing to 125 million US dollars since Versant Ventures founded the company
$125m. Described by BioPharma Dive as a private funding round; no series letter given
$75m. Led by MPM Capital; company founded by Longwood Fund and Amit Choudhary of Brigham and Women's Hospital and the Broad Institute
$25m. Co-led by Santé Ventures, Martin Ventures and LRVHealth
Series B completion announced June 2022; amount not disclosed
$45m. Series A1 extension
EUR 15 million, co-led by Crédit Mutuel Innovation and CapHorn, May 2022; over EUR 20 million raised since founding.
$261m. Total sold per Form D filed October 2022
$5m. March 2022, led by Lux Capital, per company About page
$110m. Launch announcement of 110 million US dollars total funding (seed from RA Capital and Atlas Venture plus Series A co-led by Lightspeed); the Series A portion alone is not it...
$22m. Equity offering of USD 22.09 million, first sale 17 August 2022, USD 21.54 million sold at filing
The founded year on journal records.
SAGE Publications
NEJM Group / Massachusetts Medical Society
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Nature Medicine
Future Oncology
Annals of Surgical Oncology
Lancet
The Lancet Oncology
Journal of Clinical Oncology
Communications Medicine
Nucleic Acids Research
Lancet Oncology
New England Journal of Medicine
The Lancet Regional Health - Americas
Lancet Oncology
NEJM
Indian Journal of Medical Research
Journal of Hematology & Oncology
Cancer
International Journal of Urology
Nature Communications
Recenti Progressi in Medicina
NEJM
Nature Medicine
Nature Medicine
Journal of Clinical Oncology
JAMA Network Open
Annals of Oncology
Nature Reviews Gastroenterology & Hepatology
NEJM
Nature
Scientific Reports
Blood
PLoS ONE
NEJM Evidence
NEJM
JAMA
Science Advances
JCO
JCO
Cancer Discovery
Radiotherapy and Oncology
JAMA Oncology
ESMO Open
JCO
Lancet Oncology
Blood
Annals of Oncology
The Lancet Gastroenterology & Hepatology
Nature
Annals of Surgical Oncology
European Journal of Nuclear Medicine and Molecular Imaging
Dis Colon Rectum
Future Oncology
International Journal of Cancer
British Journal of Surgery
BMJ Open
Gastroenterology
ESMO Open
Journal of Clinical Oncology
Nature Medicine
Nature Reviews Clinical Oncology
Journal of Clinical Oncology
JAMA Surgery
Journal for ImmunoTherapy of Cancer
JCO
European Urology
Journal of Clinical Oncology
Cancers
Science Translational Medicine
Endocrine, Metabolic & Immune Disorders - Drug Targets
Blood
Nature Communications
J Appl Clin Med Phys
Nature Communications
Front Oncol
JCO
New England Journal of Medicine
NEJM
Nat Genet
NEJM
Frontiers in Immunology
Microbiology Spectrum
International Journal of Surgery
NEJM
einstein (São Paulo)
European Respiratory Journal
New England Journal of Medicine
Lancet
NEJM
Seminars in Cancer Biology
Nature Medicine
Frontiers in Pediatrics
Journal of Clinical Oncology
Trials
Cancers
Clin Pharmacol Ther
Nature Communications
NEJM
Annals of Global Health
Journal of Clinical Oncology
New England Journal of Medicine
The Lancet
Cancer Discovery
Cell Reports
Lancet Oncology
Oral Oncology
NEJM
New England Journal of Medicine
NEJM
BMJ Open
Annals of Oncology
Int J Mol Sci
Journal of Cancer Policy
Journal of Experimental & Clinical Cancer Research
Expert Review of Pharmacoeconomics & Outcomes Research
American Journal of Health-System Pharmacy
NEJM
Cancer Cell
The Lancet
Leukemia
New England Journal of Medicine
NEJM
NEJM
NEJM
NEJM
NEJM Evidence
New England Journal of Medicine
NEJM
Journal of Geriatric Oncology
BMJ Open
Annals of Oncology
Blood
Das Gesundheitswesen
Blood
Lancet Oncology
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Actual primary completion date on ClinicalTrials.gov.